tiprankstipranks
Halozyme Therapeutics (CH:RV7)
NASDAQ:RV7
Switzerland Market
RV7
Halozyme
RESEARCH TOOLSreports

Halozyme (RV7) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

RV7 Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
3 Buy
2 Hold
1 Sell
Based on 6 analysts giving stock ratings to
Halozyme
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RV7 Stock 12 Month Forecast

Average Price Target

$65.48
Based on 6 Wall Street analysts offering 12 month price targets for Halozyme in the last 3 months. The average price target is $65.48 with a high forecast of $77.60 and a low forecast of $46.08. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$77.60Average Price Target$65.48Lowest Price Target$46.08
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:RV7
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF76.8
Buy
―
Reiterated
06/16/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on CH:RV7
Sean Laaman
Morgan Stanley
Morgan Stanley
CHF75.18
Buy
―
Reiterated
06/15/26
Halozyme Buy Rating Reiterated as Analyst Sees Limited Medicare Pricing Risk and Maintains $93 Price Target
Wells Fargo Analyst forecast on CH:RV7
Mohit Bansal
Wells Fargo
Wells Fargo
CHF60.63
Hold
―
Assigned
06/15/26
Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Intellia Therapeutics (NASDAQ: NTLA) and Halozyme (NASDAQ: HALO)
Goldman Sachs Analyst forecast on CH:RV7
Corinne Johnson
Goldman Sachs
Goldman Sachs
CHF46.08
Sell
―
Reiterated
06/14/26
Analysts Offer Insights on Healthcare Companies: Halozyme (NASDAQ: HALO), SAB Biotherapeutics (NASDAQ: SABS) and Design Therapeutics (NASDAQ: DSGN)
J.P. Morgan Analyst forecast on CH:RV7
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
CHF56.59
Hold
―
Reiterated
05/20/26
J.P. Morgan Sticks to Its Hold Rating for Halozyme (HALO)
TD Cowen Analyst forecast on CH:RV7
Brendan Smith
TD Cowen
TD Cowen
CHF77.6
Buy
―
Reiterated
05/11/26
Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target
Benchmark Co. Analyst forecast on CH:RV7
Robert Wasserman
Benchmark Co.
Benchmark Co.
CHF60.63→CHF72.75
Buy
―
Reiterated
02/19/26
Halozyme price target raised to $90 from $75 at BenchmarkHalozyme price target raised to $90 from $75 at Benchmark
Leerink Partners Analyst forecast on CH:RV7
David Risinger
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
01/08/26
Analysts Offer Insights on Healthcare Companies: Climb Bio (NASDAQ: CLYM) and Halozyme (NASDAQ: HALO)
Citizens JMP Analyst forecast on CH:RV7
Jason Butler
Citizens JMP
Citizens JMP
CHF73.56→CHF74.37
Buy
―
Reiterated
11/04/25
Halozyme price target raised to $92 from $91 at Citizens JMPHalozyme price target raised to $92 from $91 at Citizens JMP
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on CH:RV7
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
CHF76.8
Buy
―
Reiterated
06/16/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on CH:RV7
Sean Laaman
Morgan Stanley
Morgan Stanley
CHF75.18
Buy
―
Reiterated
06/15/26
Halozyme Buy Rating Reiterated as Analyst Sees Limited Medicare Pricing Risk and Maintains $93 Price Target
Wells Fargo Analyst forecast on CH:RV7
Mohit Bansal
Wells Fargo
Wells Fargo
CHF60.63
Hold
―
Assigned
06/15/26
Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Intellia Therapeutics (NASDAQ: NTLA) and Halozyme (NASDAQ: HALO)
Goldman Sachs Analyst forecast on CH:RV7
Corinne Johnson
Goldman Sachs
Goldman Sachs
CHF46.08
Sell
―
Reiterated
06/14/26
Analysts Offer Insights on Healthcare Companies: Halozyme (NASDAQ: HALO), SAB Biotherapeutics (NASDAQ: SABS) and Design Therapeutics (NASDAQ: DSGN)
J.P. Morgan Analyst forecast on CH:RV7
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
CHF56.59
Hold
―
Reiterated
05/20/26
J.P. Morgan Sticks to Its Hold Rating for Halozyme (HALO)
TD Cowen Analyst forecast on CH:RV7
Brendan Smith
TD Cowen
TD Cowen
CHF77.6
Buy
―
Reiterated
05/11/26
Analyst Reiterates Buy on Halozyme, Citing Underappreciated Growth and Maintaining $96 Price Target
Benchmark Co. Analyst forecast on CH:RV7
Robert Wasserman
Benchmark Co.
Benchmark Co.
CHF60.63→CHF72.75
Buy
―
Reiterated
02/19/26
Halozyme price target raised to $90 from $75 at BenchmarkHalozyme price target raised to $90 from $75 at Benchmark
Leerink Partners Analyst forecast on CH:RV7
David Risinger
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
01/08/26
Analysts Offer Insights on Healthcare Companies: Climb Bio (NASDAQ: CLYM) and Halozyme (NASDAQ: HALO)
Citizens JMP Analyst forecast on CH:RV7
Jason Butler
Citizens JMP
Citizens JMP
CHF73.56→CHF74.37
Buy
―
Reiterated
11/04/25
Halozyme price target raised to $92 from $91 at Citizens JMPHalozyme price target raised to $92 from $91 at Citizens JMP
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Halozyme

3 Months
Brendan SmithTD Cowen
Success Rate
13/18 ratings generated profit
72%
Average Return
+5.75%
Copying Brendan Smith's trades and holding each position for 3 Months would result in 72.22% of your transactions generating a profit, with an average return of +5.75% per trade.
1 Year
Brendan SmithTD Cowen
Success Rate
15/18 ratings generated profit
83%
Average Return
+14.14%
Copying Brendan Smith's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +14.14% per trade.
2 Years
Jason ButlerCitizens JMP
Success Rate
25/28 ratings generated profit
89%
Average Return
+33.43%
Copying Jason Butler's trades and holding each position for 2 Years would result in 89.29% of your transactions generating a profit, with an average return of +33.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RV7 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
1
1
1
Buy
12
10
8
8
10
Hold
2
2
1
2
3
Sell
1
0
0
0
1
Strong Sell
0
0
0
0
0
total
15
12
10
11
15
In the current month, RV7 has received 11 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. RV7 average Analyst price target in the past 3 months is 65.48.
Each month's total comprises the sum of three months' worth of ratings.

RV7 Financial Forecast

RV7 Earnings Forecast

Next quarter’s earnings estimate for RV7 is $1.44 with a range of $1.38 to $1.51. The previous quarter’s EPS was $1.27. RV7 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RV7 has Performed in-line its overall industry.
Next quarter’s earnings estimate for RV7 is $1.44 with a range of $1.38 to $1.51. The previous quarter’s EPS was $1.27. RV7 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year RV7 has Performed in-line its overall industry.

RV7 Sales Forecast

Next quarter’s sales forecast for RV7 is $319.01M with a range of $303.70M to $329.61M. The previous quarter’s sales results were $299.49M. RV7 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RV7 has Performed in-line its overall industry.
Next quarter’s sales forecast for RV7 is $319.01M with a range of $303.70M to $329.61M. The previous quarter’s sales results were $299.49M. RV7 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year RV7 has Performed in-line its overall industry.

RV7 Stock Forecast FAQ

What is CH:RV7’s average 12-month price target, according to analysts?
Based on analyst ratings, Halozyme Therapeutics’s 12-month average price target is 65.48.
    What is CH:RV7’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:RV7, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Halozyme Therapeutics a Buy, Sell or Hold?
        Halozyme Therapeutics has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 2 hold ratings and 1 sell ratings.
          What is Halozyme Therapeutics’s share price target?
          The average share price target for Halozyme Therapeutics is 65.48. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $77.60 ,and the lowest forecast is $46.08. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Halozyme Therapeutics?
            Halozyme Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
              How can I buy shares of Halozyme Therapeutics?
              To buy shares of CH:RV7, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.